India, Feb. 19 -- Chemomab Therapeutics Ltd. (CMMB), on Wednesday announced the successful completion of its End-of-Phase 2 meeting with the FDA regarding Nebokitug for the treatment of Primary Sclerosing Cholangitis.
Nebokitug is a first-in-class monoclonal antibody targeting CCL24, a protein involved in Primary Sclerosing Cholangitis' inflammatory and fibrotic processes.
Primary Sclerosing Cholangitis (PSC) is a deadly liver disorder, having no approved therapies. Its symptoms include fatigue, pruritis, abdominal pain and jaundice.
The FDA has agreed to a streamlined design for a Phase 3 registration trial, which, for the first time, will focus on clinical events associated with PSC disease progression.
The trial will not require live...